{"id":"W4410809556","doi":"10.1200/jco.2025.43.16_suppl.6500","title":"Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Anagrelide; Essential thrombocythemia; Internal medicine; Oncology; Pediatrics; Polycythemia vera","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00189095,0.001007214,0.001355023,0.0002649237,0.0002235048,0.0008647655,0.000530072,0.000907753,0.004730692],"category_scores_gemma":[0.001105572,0.0003135059,0.00123571,0.0002116939,0.0004306747,0.0009417034,0.0002722711,0.001936975,0.0005273386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005573656,"about_ca_system_score_gemma":0.000632151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005322754,"about_ca_topic_score_gemma":0.001638042,"domain_scores_codex":[0.9996364,0.0002091188,0.00002163635,0.00004245468,0.00003605169,0.0000542588],"domain_scores_gemma":[0.9993006,0.0001980221,0.0001538035,0.00004207318,0.0000286095,0.0002769583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9247423,0.006657385,0.001750105,0.0007415688,0.001507352,0.0001323131,0.0001246011,0.001342301,0.008290458,0.0003952464,0.004075143,0.05024114],"study_design_scores_gemma":[0.8925189,0.09454741,0.006337434,0.00007711865,0.0008834747,0.000225333,0.00003811986,0.001397186,0.0009516332,0.0004188832,0.002580523,0.00002410475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802644,0.009999825,0.000686944,0.001058766,0.0002183806,0.001344509,0.002189547,0.0001210875,0.004116357],"genre_scores_gemma":[0.9838243,0.004065214,0.001669295,0.001687654,0.0003742923,0.001499304,0.003017321,0.00003890712,0.003823713],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004730692,"threshold_uncertainty_score":0.01582575,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1972729835066012,"score_gpt":0.5520955850902599,"score_spread":0.3548226015836587,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}